BI-1808

DRUG2 trials

Sponsors

BioInvent International AB

Conditions

Advanced MalignanciesAdvanced solid tumorsMelanomaOvarian CancerT-cell Lymphoma

Phase 1

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

RecruitingNCT04752826

BioInvent International ABAdvanced Malignancies, Melanoma, Ovarian Cancer +1

Start: 2021-01-25End: 2028-01-15Target: 176Updated: 2026-02-18

Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies

RecruitingCTIS2023-509847-29-00

BioInvent International ABAdvanced solid tumors

Start: 2020-04-09Target: 141Updated: 2025-12-15

Related Papers

19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab.

Journal of Clinical Oncology2024-06-013 citations